Title :

Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma.

Author(s) :

Bertrand, Nicolas [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Guerreschi, Pierre [Auteur]
Advanced Drug Delivery Systems (ADDS) - U1008
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Basset-Seguin, Nicole [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Saiag, Philippe [Auteur]
Hôpital Ambroise Paré [AP-HP]
Dupuy, Alain [Auteur]
Centre Hospitalier Universitaire [Rennes]
Dalac-Rat, Sophie [Auteur]
Service de Dermatologie (CHU de Dijon)
Dziwniel, Véronique [Auteur]
Centrale Lille
Depoortère, César [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Duhamel, Alain [Auteur]
Service de Biostatistiques [CHRU Lille]
Mortier, Laurent [Auteur]
Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 [OncoThAI]

Journal title :

EClinicalMedicine

Volume number :

35

Pages :

100844

Publisher :

Elsevier

Publication date :

2021-05-23

ISSN :

2589-5370

Keyword(s) :

Locally advanced basal cell carcinoma
Neoadjuvant
Vismodegib

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Surgery is the primary treatment for basal cell carcinoma (BCC). In locally advanced basal cell carcinoma (laBCC), surgery may cause functional or aesthetic damage. In laBCC, neoadjuvant administration of vismodegib, an ...
Show more >Surgery is the primary treatment for basal cell carcinoma (BCC). In locally advanced basal cell carcinoma (laBCC), surgery may cause functional or aesthetic damage. In laBCC, neoadjuvant administration of vismodegib, an inhibitor of the Hedgehog signaling pathway, may reduce tumor size, facilitate resection, and reduce functional and aesthetic consequences of surgery. The VISMONEO study assessed efficacy and safety of vismodegib in neoadjuvant treatment of laBCC.Show less >

Language :

Anglais

Audience :

Internationale

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Advanced Drug Delivery Systems (ADDS) - U1008

Submission date :

2022-12-08T01:26:56Z
2023-02-08T09:14:39Z